LONDON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting…
In the Phase I clinical trial, participants were administered SPL026 and underwent a 20-minute psychedelic experience Phase I full dataset demonstrates consistent dose related effects…